NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.

Autor: Hoppe RT; Stanford Cancer Institute., Advani RH; Stanford Cancer Institute., Ai WZ; UCSF Helen Diller Family Comprehensive Cancer Center., Ambinder RF; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins., Armand P; Dana-Farber/Brigham and Women's Cancer Center., Bello CM; Moffitt Cancer Center., Benitez CM; UCLA Jonsson Comprehensive Cancer Center., Chen W; UT Southwestern Simmons Comprehensive Cancer Center., Dabaja B; The University of Texas MD Anderson Cancer Center., Daly ME; UC Davis Comprehensive Cancer Center., Gordon LI; Robert H. Lurie Comprehensive Cancer Center of Northwestern University., Hansen N; Fred & Pamela Buffett Cancer Center., Herrera AF; City of Hope National Medical Center., Hochberg EP; Massachusetts General Hospital Cancer Center., Johnston PB; Mayo Clinic Cancer Center., Kaminski MS; University of Michigan Rogel Cancer Center., Kelsey CR; Duke Cancer Institute., Kenkre VP; University of Wisconsin Carbone Cancer Center., Khan N; Fox Chase Cancer Center., Lynch RC; Fred Hutchinson Cancer Research Center/University of Washington., Maddocks K; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., McConathy J; O'Neal Comprehensive Cancer Center at UAB., Metzger M; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center., Morgan D; Vanderbilt-Ingram Cancer Center., Mulroney C; UC San Diego Moores Cancer Center., Pullarkat ST; UCLA Jonsson Comprehensive Cancer Center., Rabinovitch R; University of Colorado Cancer Center., Rosenspire KC; Abramson Cancer Center at the University of Pennsylvania., Seropian S; Yale Cancer Center/Smilow Cancer Hospital., Tao R; Huntsman Cancer Institute at the University of Utah., Torka P; Roswell Park Comprehensive Cancer Center., Winter JN; Robert H. Lurie Comprehensive Cancer Center of Northwestern University., Yahalom J; Memorial Sloan Kettering Cancer Center., Yang JC; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; and., Burns JL; National Comprehensive Cancer Network., Campbell M; National Comprehensive Cancer Network., Sundar H; National Comprehensive Cancer Network.
Jazyk: angličtina
Zdroj: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2022 Apr; Vol. 20 (4), pp. 322-334.
DOI: 10.6004/jnccn.2022.0021
Abstrakt: Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.
Databáze: MEDLINE